Alpine BioVentures
3
31M
2
1
0.33
1
- Areas of investment
Summary
The main department of described VC is located in the Seattle. The venture was found in North America in United States.
This organization was formed by Mitchell H. Gold.
The standard case for the fund is to invest in rounds with 2-3 partakers. The meaningful sponsors for the fund in investment in the same round are Frazier Healthcare Partners, OrbiMed.
For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Besides, a startup requires to be at the age of 1 and less years to receive the investment from the fund. Among the most popular fund investment industries, there are Pharmaceutical, Health Care. Among the most popular portfolio startups of the fund, we may highlight Alpine Immune Sciences.
Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is generally included in less than 2 deals every year. The high activity for fund was in 2016.
Investments analytics
Analytics
- Total investments
- 3
- Lead investments
- 1
- Exits
- 1
- Follow on index
- 0.33
- Investments by industry
- Biotechnology (3)
- Health Care (3)
- Medical (2)
- Life Science (1)
- Pharmaceutical (1)
- Investments by region
-
- United States (3)
- Peak activity year
- 2016
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 6
- Group Appearance index
- 1.00
- Avg. company exit year
- 3
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Mavupharma | 29 Nov 2017 | Biotechnology, Health Care, Life Science, Pharmaceutical | Early Stage Venture | 20M | United States, Washington |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.